21 CFR Part 1271 · Human Cells, Tissues, and Cellular and Tissue-Based Products

21 CFR 1271.2

21 CFR 1271.2 is the regulation in 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Since 2021, 7 FDA warning letters have cited it.

Letters citing it
7 since 2021
Jan 1 to Oct 30, 2026
2 against 1 on the same dates in 2025
Most often cited with
21 CFR 1271.10, in 7 letters
Closed out
0% of these letters have a published close-out
See the 7 letters citing 21 CFR 1271.2 →

Letters citing it, by year issued

All are biologics letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 02021
  2. 02022
  3. 02023
  4. 22024
  5. 32025
  6. 22026

The regulation

The text of this section is not in the saved copy.

Text from eCFR.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 1271.2.

Latest letters citing it

The 3 letters citing 21 CFR 1271.2 that FDA posted most recently.

See the 7 letters citing 21 CFR 1271.2 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.